Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors

Author(s): Francesca Musumeci, Monica Sanna, Giancarlo Grossi, Chiara Brullo, Anna Lucia Fallacara, Silvia Schenone*

Journal Name: Current Medicinal Chemistry

Volume 24 , Issue 19 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


The pyrrolo[2,3-d]pyrimidine nucleus is a deaza-isostere of adenine, the nitrogenous base of ATP, and is present in many ATP-competitive inhibitors of different kinases. In the last few years the number of articles and patents that have appeared involving this type of inhibitors has dramatically increased and some compounds have been approved for the treatment of inflammatory or myeloproliferative diseases. Other derivatives are currently being evaluated in clinical trials. This review deals with pyrrolo[2,3- d]pyrimidine derivatives active as kinase inhibitors that have been reported in the literature from 2011 to 2016, with a particular interest on the recently patented compounds. The molecules are classified depending on the inhibited kinase, focusing on their chemical structures.

Keywords: Pyrrolo[2, 3-d]pyrimidine, kinase inhibitors, patents, anticancer agents, anti-inflammatory agents.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 03 March, 2017
Page: [2059 - 2085]
Pages: 27
DOI: 10.2174/0929867324666170303162100
Price: $65

Article Metrics

PDF: 61
HTML: 16
PRC: 2